Evidence map›Paper›PMID 17713804›Full record

Trial reportLipids2007

Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food.

Linda M Arterburn, Harry A Oken, James P Hoffman, Eileen Bailey-Hall, Gloria Chung, Dror Rom, Jacqueline Hamersley, Deanna McCarthy

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Lipids, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01061554 (Correlation Between Level of Polyunsaturated Fatty Acid EPA and DHA in Blood After Digestion of ProBios Omega-3 Concordix™ Compared With Omega-3 Soft Capsules - a Pilot), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01061554 phase1completednot on this mapstarted 2009, after this paper: background citation

Correlation Between Level of Polyunsaturated Fatty Acid EPA and DHA in Blood After Digestion of ProBios Omega-3 Concordix™ Compared With Omega-3 Soft Capsules - a Pilot

TypeinterventionalSponsorAyanda ASRan2009 to 2009Enrolled27ConditionsHealthyArmsOmega-3 oils from tri-glycerides, Omega-3 oils from marine phospholipids
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 134 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Ultrasonic-assistedFood chemistry: X · 2025
    Article
  7. Article
  8. Metabolic Engineering ofACS engineering Au · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Valorisation of algal biomass to value-added metabolites: emerging trends and opportunities.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Linda M ArterburnMartek Biosciences Corporation, 6480 Dobbin Road, Columbia, MD 21045, USA.
Harry A Oken
James P Hoffman
Eileen Bailey-Hall
Gloria Chung
Dror Rom
Jacqueline Hamersley
Deanna McCarthy
University of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docosahexaenoic acid (DHA), a long-chain omega-3 fatty acid, is important for eye and brain development and ongoing visual, cognitive, and cardiovascular health. Unlike fish-sourced oils, the bioavailability of DHA from vegetarian-sourced (algal) oils has not been formally assessed. We assessed bioequivalence of DHA oils in capsules from two different algal strains versus bioavailability from an algal-DHA-fortified food. Our 28-day randomized, placebo-controlled, parallel group study compared bioavailability of (a) two different algal DHA oils in capsules ("DHASCO-T" and "DHASCO-S") at doses of 200, 600, and 1,000 mg DHA per day (n = 12 per group) and of (b) an algal-DHA-fortified food (n = 12). Bioequivalence was based on changes in plasma phospholipid and erythrocyte DHA levels. Effects on arachidonic acid (ARA), docosapentaenoic acid-n-6 (DPAn-6), and eicosapentaenoic acid (EPA) were also determined. Both DHASCO-T and DHASCO-S capsules produced equivalent DHA levels in plasma phospholipids and erythrocytes. DHA response was dose-dependent and linear over the dose range, plasma phospholipid DHA increased by 1.17, 2.28 and 3.03 g per 100 g fatty acid at 200, 600, and 1,000 mg dose, respectively. Snack bars fortified with DHASCO-S oil also delivered equivalent amounts of DHA on a DHA dose basis. Adverse event monitoring revealed an excellent safety and tolerability profile. Two different algal oil capsule supplements and an algal oil-fortified food represent bioequivalent and safe sources of DHA.

Indexed as

Food, FortifiedAdolescentAdultAgedArachidonic AcidCapsulesDietary Fats, UnsaturatedDietary SupplementsDocosahexaenoic AcidsDouble-Blind MethodEicosapentaenoic AcidErythrocytesEukaryotaFatty Acids, UnsaturatedFemaleHumansArachidonic AcidCapsulesDietary Fats, UnsaturatedDocosahexaenoic Acidsdocosapentaenoic acidEicosapentaenoic AcidFatty Acids, UnsaturatedPhospholipidsPlacebos

Identifiers

PMID17713804
OpenAlexW2017776734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.